SCHEMBL4519232

SCHEMBL4519232

COc1ccccc1NC(=O)c1n[nH]c2ccccc12.Cc1ccc(NC(=O)c2n[nH]c3ccccc23)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.57
MAP4K1 Q92918 1/20 0.56
EPHB3 P54753 1/20 0.54
CDK2 P24941 2/20 0.54
NPC1 O15118 3/20 0.53
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CTNNB1 P35222 1/20 0.50
WNT3A P56704 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
CSNK2A1 P68400 1/20 0.49
GFER P55789 1/20 0.49
CCNA2 P20248 1/20 0.49
CCNA1 P78396 1/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
HIF1A Q16665 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951232 0.89 EPHB3 (0.66) FLT3MAP4K1EPHB3CDK2NPC1
SCHEMBL4524085 0.81 FLT3 (0.83) FLT3MAP4K1EPHB3CDK2NPC1
SCHEMBL954628 0.81 EPHB3 (0.71) FLT3MAP4K1EPHB3CDK2KDM4E
SCHEMBL1600113 0.77 FLT3 (0.56) FLT3MAP4K1EPHB3CDK2NPC1
SCHEMBL29176629 0.73 FLT3 (1.00) FLT3MAP4K1CDK2CTNNB1WNT3A
SCHEMBL30695138 0.73 FLT3 (1.00) FLT3MAP4K1CDK2CTNNB1WNT3A
SCHEMBL955081 0.71 EPHB3 (1.00) FLT3MAP4K1EPHB3CDK2NPC1
SCHEMBL13502778 0.71 EPHB3 (0.71) FLT3MAP4K1EPHB3CDK2NPC1
SCHEMBL91568 0.70 EPHX1 (0.49) NPC1KDM4EALDH1A1GAAMEN1
SCHEMBL92544 0.70 MAPT (0.58) MAPTLMNATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2006-01-05 US claimed
US-7482342-B2 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors CDK2, CDK1, CDK4 FLT3 255/4885MAP4K1 384/4885EPHB3 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.